Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review

Bibliography

• ABRAMS P, CARDOZO L, FALL M et al.: The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology (2003) 61:37–49.
   PubMed Web of Science ®Google Scholar
• ABRAMS P, WEIN AJ: The overactive bladder: from basic science to clinical management consensus conference. Urology (1997) 50(Suppl.):1–114.
   Google Scholar
• ABRAMS P, WEIN AJ: Overactive bladder and its treatments consensus conference. Urology (2000) 55(Suppl.):1–84.
   Google Scholar
• STASKIN DR, WEIN AJ: New perspectives on the overactive bladder. Urology (2002) 60(Suppl.):1–104.
   Google Scholar
• ABRAMS P, CARDOZO L, FALL M et al.: The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn. (2002) 21:167–178.
   PubMed Web of Science ®Google Scholar
• VAN KERREBROECK P, ABRAMS P, CHAIKIN D et al.: The standardization of terminology in nocturia: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn. (2002) 21:179–183.
   PubMed Web of Science ®Google Scholar
• JOHNSON TM II, KINCADE JE, BERNARD SL et al.: The association of urinary incontinence with poor self-rated health. Am. Geriatr. Soc. (1998) 46:693–699.
   PubMedGoogle Scholar
• TEMML C, HAIDINGER G, SCHMIDBAUER J, SCHATZL G, MADERSBACHER S: Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. Neurourol Urodyn. (2000) 19:259–271.
   PubMed Web of Science ®Google Scholar
• WYMAN JF, HARKINS SW, FANTL JA:Psychosocial impact of urinary incontinence in the community-dwelling population. J. Am. Geriatr. Soc. (1990) 38:282–288.
   PubMed Web of Science ®Google Scholar
• DUGAN E, COHEN SJ, BLAND DR et al.: The association of depressive symptoms and urinary incontinence among older adults. Am. Geriatr. Soc (2000) 48:413–416.
   PubMed Web of Science ®Google Scholar
• BROWN JS, VITTINGHOFF E, WYMAN JF et al: Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J. Am. Geriatr. Soc. (2000) 48:721–725.
   PubMed Web of Science ®Google Scholar
• HERZOG AR, FULTZ NH: Prevalence and incidence of urinary incontinence in community-dwelling populations. J. Am. Geriatr. Soc. (1990) 38:273–281.
   PubMed Web of Science ®Google Scholar
• THOM D: Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J. Am. Geriatr. Soc. (1998) 46:473–480.
   PubMed Web of Science ®Google Scholar
• MILSON I, ABRAMS P, CARDOZO L, ROBERTS RG, THUROFF J, WEIN AJ: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br: J. Um]. Int. (2001) 87:760–766.
   Google Scholar
• STEWART W, HERZOG R, WEIN A et al.: Prevalence and impact of overactive bladder in the US: results for the NOBLE program. Neurourol Urodyn. (2001) 20:406 (Abstract).
   Google Scholar
• WAGNER TH, HU TW: Economic costs of urinary incontinence in 1995. Urology (1998) 51:355.
   PubMed Web of Science ®Google Scholar
• WAGNER TH, HU TW: Economic costs of urinary incontinence. Int. Urogynecol Pel Fl. Dys. (1998) 9:127.
   PubMedGoogle Scholar
• HU TW, MOORE K, SUBAK L et al: Economics of incontinence. In: Incontinence (2'd edn) Abrams P, Cardozo L, Khoury S, Wein A (Eds), Health Publications, Plymouth, UK (2002):3–20.
   Google Scholar
• LENDERKING WR, NACKLEY JF, ANDERSON RB, TESTA MA: A review of the quality-of-life aspects of urinary urge incontinence. Pharmacoeconomics (1996) 9:11.
   PubMed Web of Science ®Google Scholar
• CHANCELLOR MB, YOSHIMURA N: Physiology and pharmacology of the bladder and urethra. In: Campbell S Urology edn I Walsh PC, Retik AB, Vaughan ED, Wein AJ (Eds), WB Saunders Co., Philadelphia, USA (2002):831–886.
   Google Scholar
• YOKOYAMA 0: Glutamatergic and dopaminergic contributions to rat bladder hyperactivity after cerebral artery occlusion. Am. J. Physic] (1999) 276:R935–R942.
   Google Scholar
• BRADING AF: A myogenic basis for theoveractive bladder. Urology (1997) 50:57.
   PubMed Web of Science ®Google Scholar
• JUNG SY, FRASER MO, OZAWA H et al.: Urethral afferent nerve activity affects the micturition reflex; implication for the relationship between stress incontinence and detrusor instability. J. Um]. (1999) 162:204.
   Google Scholar
• WEIN AJ: Pharmacology of incontinence.Um]. Clin. North Am. (1995) 22:557–577.
   PubMed Web of Science ®Google Scholar
• WANG P, LUTHIN GR, RUGGIERI MR: Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. Pharmacol Exp. Ther: (1995) 273:959–966.
   PubMed Web of Science ®Google Scholar
• YAMANISHI T, YASUDA K, CHAPPLE CR, CHESS-WILLIAMS R: The role of M2-muscarinic receptors in mediating contraction of the pig urinary bladder in vitro. Br. J. Pharmacol (2001) 31:1482–1488.
   Google Scholar
• CHOPPIN A, EGLEN RM, HEGDE SS:Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle. Br. J. Pharmacol (1998) 124:883–888.
   PubMedGoogle Scholar
• SELLERS DJ, YAMANISHI T, CHAPPLE CR et al: M3 muscarinic receptors but not M2 mediate contraction of the porcine detrusor muscle in vitro. Auton. Pharmacol (2000) 20:171–176.
   PubMedGoogle Scholar
• CHESS-WILLIAMS R, CHAPPLE CR, YAMANISHI T, SELLERS SJ: The minor population of M3 receptors mediate contraction of human detrusor muscle in vitro. Auton. Pharmacol (2002) 21(5-6):243–248.
   Google Scholar
• SOMOGYI GT, DE GROAT WC: Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Life Sci. (1998) 64:411.
   Google Scholar
• HAY-SMITH J, HERBISON P, ELLIS G, MOORE K: Anticholinergic drugs versus placebo for overactive bladder syndrome in adults [Cochrane Review]. In: Cochrane Library (issue D. John Wiley & Sons, Chichester, UK (2003).
   Google Scholar
• NILVEBRANT L, ANDERSSON KE, GILLBERG PG et al: Tolterodine: a new bladder-selective antimuscarinic agent. Eur.j Pharmacol (1997) 327:195.
   PubMed Web of Science ®Google Scholar
• ABRAMS P, FREEMAN R, ANDERSTROM C, MATTIASSON A: Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br: J. Urol. (1998) 81:801–810.
   PubMedGoogle Scholar
• JONAS U, HOFNER K, MADERSBACHER H, HOLMDAHL TH: Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J. Urol. (1997) 15:144–151.
   PubMed Web of Science ®Google Scholar
• DRUTZ HP, APPELL RA, GLEASON D, KLIMBERG I, RADOMSKI S: Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int. Urogynecol Pei D. Dysfunct. (1999)10:283–289.
   PubMedGoogle Scholar
• VAN KERREBROECK P, KREDER K, JONAS U, ZINNER N, VVEIN A: Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology (2001) 57:414–421.
   PubMed Web of Science ®Google Scholar
• MALONE-LEE J, SHAFFU B, ANAND C, POWELL C: Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. .1 Urol. (2000)165:1452–1456.
   Google Scholar
• MALONE-LEE JG, WALSH JB, MAUGOURD MF: Tolterodine: a safe and effective treatment for older patients with overactive bladder. J. Am. Ceriatr. Soc. (2001) 49:700–705.
   Google Scholar
• ZINNER NR, MATTIASSON A, STANTON SL: Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J. Am. Ceriatr. Soc. (2002) 50:799–807.
   Google Scholar
• SUSSMAN D, GARELY A: Treatment ofoveractive bladder with once-daily extended-release tolterodine or oxybutynin: the Antimuscarinic Clinical Effectiveness Trial (ACET). Curr: Med. Res. Opin. (2002) 18:177–184.
   PubMed Web of Science ®Google Scholar
• GULLIFORD G, BIDMEAD J: Management of incontinence. Pharm. J. (2001) 267:230–232.
   Google Scholar
• MAZUR D, WEHNERT J, DORSCHNER W, SCHUBERT G, HERFURTH G, ALKEN RG: Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence: a multicentre dose-optimizing study. Scand. I Urol. Nephrol (1995) 29:289–294.
   PubMed Web of Science ®Google Scholar
• FUSGEN I, HAURI D: Trospium chloride: an effective option for medical treatment of bladder overactivity. bit. .1 Clin. Pharmacol Ther. (2000) 38:223–234.
   Google Scholar
• BOOTH C, PASCOE D: A comparison of newer drug treatments for urinary incontinence. Hosp. Pharm. (2002) 9:69–75.
   Google Scholar
• NAPIER C, GUPTA P: Darifenacin is selective for the human recombinant M3 receptor subtype. Trial 445. Pfizer, Inc., NY, USA (2002):1–2.
   Google Scholar
• CHAPPLE, CR, ARANO P, BOSCH JHR et al.: YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled Phase II-dose finding study. Neurourol Urodyn. (2002) 21(Suppl.):381.
   Google Scholar
• FANTL JA, NEWMAN DK, COLLING J: Urinary incontinence in adults: acute and chronic management. Clinical Practice Guideline. Rockville, Maryland: United States Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research, No. 2, (1996).
   Google Scholar
• THOMPSON IM, LAUVETZ R: Oxybutynin in bladder spasm, neurogenic bladder, and enuresis. Urology (1976) 8:452.
   PubMedGoogle Scholar
• ALZA Corporation: Ditropan® (oxybutynin chloride) extended-release tablets, prescribing information (2004). ALZA Corporation, USA.
   Google Scholar
• PORTERA SG, LIPSCOMB GH: Pharmacologic therapy for urinary incontinence and voiding dysfunction. Clin. Obstet. Cynecol (1998) 41:691–701.
   PubMed Web of Science ®Google Scholar
• SATHYAN D, CHANCELLOR M, GUPTA S: Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br: J. Clin. Pharmacol (2001) 51:409–417.
   Web of Science ®Google Scholar
• DOHERTY MM, CHARMAN WN: The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin. Pharmacokinet. (2002) 41:235.
   PubMed Web of Science ®Google Scholar
• COMER AM, GOA KL: Extended-release oxybutynin. Drugs Aging (2000) 16:149.
   PubMed Web of Science ®Google Scholar
• GUPTA S, SATHYAN G: Pharmokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. Clin. Pharmacol (1999) 39:289–296.
   Google Scholar
• APPELL R, CHANCELLOR M, ZOBRIST H et al: Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin. Proc. (2003) 78:696–702.
   PubMed Web of Science ®Google Scholar
• BRENDLER CB, RADEBAUGH LC, MOHLER JL: Topical oxybutynin chloride for relaxation of dysfunctional bladders. Urol. (1989) 141:1350–1352.
   Google Scholar
• YOSHIMURA N, CHANCELLOR MB: Current and future pharmacological treatment for overactive bladder. J. Urol. (2002) 168:1897–1913.
   PubMed Web of Science ®Google Scholar
• BOONE TB, APPELL RA, LOPEZ MA et al.: Pharmacokinetic evaluation of intravesical oxybutynin: bolus and continuous delivery. J. Urol. (2001) 165(Suppl.):252 (Abstract 1039).
   Google Scholar
• CHAPPLE C: Muscarinic receptor antagonists in the treatment of overactive bladder. Urology (2000) 55(Suppl. 5A):33–45.
   Google Scholar
• SCHRODER A, LEVIN R, KOGAN B et al.: Absorption of oxybutynin from vaginal inserts: drug blood levels and the response of the rabbit bladder. Urology (2000) 56:1063–1067.
   PubMed Web of Science ®Google Scholar
• COLLAS D, MALONE-LEE J: The pharmacolkinetic properties of rectal oxybutynin: a possible alternative to intravesical administration. Neurourol Urodyn. (1997) 16:346–489.
   Google Scholar
• GAJEWSKI JB, AWAD SA: Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. Urol (1986) 135:966.
   Google Scholar
• ZEEGERS AGM, KIESWETTER H, KRAMER AEJL, JONAS U: Conservative therapy of frequency, urgency and urge incontinence: a double-blind clinical trial of flavoxate hydrochloride, oxybutynin chloride, emepronium bromide and placebo. World J. Um]. (1987) 5:57.
   Google Scholar
• GUPTA SK, SATHYAN G: Pharmacolkinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. Clin. Pharmacol (1999) 39:289–296.
   Google Scholar
• ANDERSON RU, MOBLEY D, BLANK B, SALTZSTEIN D, SUSSET J, BROWN JS: Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence." Um]. (1999) 161:1809–1812.
   Google Scholar
• GLEASON DM, SUSSET J, WHITE C, MUNOZ DR, SAND PK: Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology (1999) 54:420–423.
   PubMed Web of Science ®Google Scholar
• BIRNS J, LUKKARI E, MALONE-LEE JG: A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. Br: J. Urol. (2000) 85:793–798.
   Google Scholar
• APPELL RA, SAND P, DMOCHOWSKI R et al.: Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin. Proc. (2001) 76:358–63.
   PubMed Web of Science ®Google Scholar
• •The only available head-to-head, randomised, double-blind trial, comparing the outcomes of extended-release oxybutynin to immediate-release tolterodine.
   Google Scholar
• NILSSON CG, LUKKARI E, HAARALA M et al.: Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. Neurourol Urodyn. (1997) 16:533–542.
   PubMed Web of Science ®Google Scholar
• BIRNS J, MALONE LEE JG, and the OXYBUTYNIN CR STUDY GROUP: Controlled-release oxybutynin maintains efficacy with a 43% reduction in side effects compared with conventional oxybutynin treatment. Neurourol Urodyn. (1997) 16:429–430.
   Google Scholar
• SCHMIDT RA, and the OXYBUTYNIN XL STUDY GROUP: Efficacy of controlled-release, once-a-day oxybutynin chloride for urge urinary incontinence. Presented at: International Continence Society Jerusalem. September 14–17, (1998).
   Google Scholar
• ZINNER NR: Patient-oriented outcomes with once-daily oxybutynin for urge incontinence. °Lister Cynecol (1999) 93(Suppl.):29 (Abstract).
   Google Scholar
• DAVILA GW, DAUGHERTY CA, SANDERS SW: A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J. Um]. (2001) 166:140–145.
   Google Scholar
• DMOCHOWSKI RR, DAVILA GW, ZINNER NR et al.: Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J. Um]. (2002) 168:580–586.
   Google Scholar
• MADERSBACHER H, JILG G: Control of detrusor hyperreflexia by the intravesical instillation of oxybutynin hydrochloride. Paraplegia (1991) 29:84.
   PubMedGoogle Scholar
• SAITO M, TABUCHI F, OTSUBO K, MIYAGAWA I: Treatment of overactive bladder with modified intravesical oxybutynin chloride. Neurourol Urodyn. (2000) 19:683.
   PubMed Web of Science ®Google Scholar
• PANNEK J, SOMMERFELD HJ, BOTEL U, SENGE T: Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury. Urology (2000) 55:358.
   PubMedGoogle Scholar
• ENZELSBERGER H, HELMER H, KURZ CH: Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomized trial. Br. J. Obster Cynaecol. (1995) 102:929–930.
   PubMedGoogle Scholar
• GREENFIELD SP FERA M: The use of intravesical oxybutynin chloride in children with neurogenic bladder. J. Um]. (1991) 146:532.
   Google Scholar
• WEESE DL, ROSKAMP DA, LEACH GE, ZIMMERN PE: Intravesical oxybutynin chloride: experience with 42 patients. Urology (1993) 41:527.
   PubMedGoogle Scholar
• PRASAD KV, VAIDYANATHAN S: Intravesical oxybutynin chloride and clean intermittent catheterization in patients with neurogenic vesical dysfunction and decreased bladder capacity. Br. .1. Um]. (1993) 72:719.
   PubMedGoogle Scholar
• KASABIAN NG, VLACHIOTIS JD, LAIS A, KLUMPP B, KELLY MD, SIROKY MB et al.: The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia. Urol (1994) 151:944.
   Google Scholar
• MIZUNAGA M, MIYATA M, KANEKO S, YACHIKU S, CHIBA K: Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder. (1994) Paraplegia 32:25.
   Google Scholar
• CONNOR JP, BETRUS G, FLEMING P, PERLMUTTER AD, REITELMAN C: Early cystometrograms can predict the response to intravesical instillation of oxybutynin chloride in myelomeningocele patients. Um]. (1994) 151:1045.
   Google Scholar
• KAPLINSKY R, GREENFIELD S, WAN J, FERA M: Expanded follow-up of intravesical oxybutynin chloride use in children with neurogenic bladder. Urol (1996) 156:753.
   Google Scholar
• PAINTER KA, VATES TS, BUKOWSKI TP et al.: Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia. Urol (1996) 156:1459.
   Google Scholar
• SZOLLAR SM, LEE SM: Intravesical oxybutynin for spinal cord injury patients. Spinal Cord, (1996) 34:284.
   PubMedGoogle Scholar
• WINKLER HA, SAND PK: Treatment of detrusor instability with oxybutynin rectal suppositories. Int. Urogynecol I Pelvic Door Dysfunct. (1998) 9:100–102.
   PubMedGoogle Scholar
• BAIGRIE RJ, KELLEHER JP, FAWCETT DP et al: Oxybutynin: is it safe? Br J. Um]. (1988) 62:319–322.
   Google Scholar
• YARKER YE, GOA KL, FITTON A: Oxybutynin. A review of its pharmacodynamic and pharmacolkinetic properties, and its therapeutic use in detrusor instability. Drugs Aging (1995) 6:243.
   Google Scholar
• TAPP AJS, CARDOZO LD, VERSI E, COOPER D: The treatment of detrusor instability in postmenopausal women with oxybutynin chloride: a double blind placebo controlled study. Br. .1. Obstet. Gynaecol (1990) 97:521–526.
   PubMedGoogle Scholar
• RIVA D, CASOLATI E: Oxybutynin chloride in the treatment of female idiopathic bladder instability. Clin. Exp. Obstet. Gynecol (1984) 11:37–42.
   PubMedGoogle Scholar
• MOVIG KLL, EGBERTS ACG, LENDERINK AW, LEUFKENS HGM: Association between oxybutynin and neuropsychiatric adverse effects not confirmed in daily practice. J. Am. Geriam. Soc. (2001) 49:234–235.
   PubMedGoogle Scholar
• KATZ IR, SANDS LP, BILKER E et al.: Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J. Am. Geriam. Soc. (1998) 46:8–13.
   PubMed Web of Science ®Google Scholar
• DONNELLAN CA, FOOK L, MCDONALD P, PLAYFER JR: Oxybutynin and cognitive dysfunction. Br. Med. J. (1997) 315:1363–1364.
   PubMed Web of Science ®Google Scholar
• TODOROVA A, VONDERHEID-GUTH B, DIMPFEL W: Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. Clin. Pharmacol (2001) 41:636–44.
   Google Scholar
• ARIKIAN SR, CASCIANO J, DOYLE JJ et al.: A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Manag. Care Interfac. (2000) 13(2):88–94.
   PubMedGoogle Scholar
• LEUNG HY, YIP SK, CHEON C et al: A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. BIU Int. (2002) 90:375–380.
   Google Scholar
• LEE JG, HONG JY, CHOO MS et al.: Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int. J. Urol. (2002) 9:247–252.
   PubMed Web of Science ®Google Scholar
• APPELL RA: Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology (1997) 50:90.
   PubMed Web of Science ®Google Scholar
• DIOKNO AC, APPELL RA, SAND PK et al.: Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo. Clin. Proc. (2003) 78:687–695.
   PubMed Web of Science ®Google Scholar
• ••The only available head-to-head,randomised, double-blind, controlled trial, comparing the outcomes of extended-release oxybutynin to those of extended-release tolterodine.
   Google Scholar
• DMOCHOWSKI RR, SAND PK, ZINNER NR, GITTELMAN MC, DAVILA GW, SANDERS SW. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology (2003) 62:237–242.
   PubMed Web of Science ®Google Scholar
• MADERSBACHER H, HALASKA M, VOIGHT R et al.:A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. Br. .1 Urol. Int. (1999) 84:646–651.
   Google Scholar
• MADERSBACHER H, MURTZ G: Efficacy, tolerability and safety profile in propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J. Urol. (2001) 19:324–335.
   PubMed Web of Science ®Google Scholar
• MADERSBACHER H, STOHRER M, RICHTER R, BURGDORFER H, HACHEN HJ, MURTZ G: Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J. Urol. (1995)75:452–456.
   PubMedGoogle Scholar
• THUROFF JVV, BUNKE B, EBNER A et al.: Randomized, double blind, multicentre trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Urol. (1991) 145:813–817.
   Google Scholar
• HOLMES DM, MONTZ FJ, STANTON SL: Oxybutynin versus propantheline in the management of detrusor instability: a patient-regulated variable dose trial. Br. J. Obstet. Gynaecol (1989) 96:607–612.
   PubMedGoogle Scholar